NEW YORK, NY / ACCESSWIRE / December 22, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Clearmind Medicine.

Toni had the pleasure of recently conducting the Interview with Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani (NASDAQ:CMND). Toni diligently focused on questions she thought would be on the minds of most current and potential future shareholders. See interview highlights below.

Access this interview in its entirety at https://tradersnewssource.com/cmnd-interview/

Adi Zuloff-Shani, PhD

Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with a vast experience with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.

Interview Highlights:

Traders News Source Editor Toni Loudenbeck and Adi Zuloff-Shani, PhD discuss an overview of the company, the history of MEAI and its development into the CMND-100 product, the company's IP portfolio, what near term catalyst at CMND could be the biggest benefit to shareholders plus much more in this interview.

Access this interview in its entirety at https://tradersnewssource.com/cmnd-interview/

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company's intellectual portfolio currently consists of seven patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND", the Canadian Securities Exchange under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol "CWY".

For further information, please contact:

Investor Relations,
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: (604) 260-1566

General Inquiries,
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.Clearmindmedicine.com

About Traders News Source (TNS)

Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit: https://tradersnewssource.com/cmnd-interview/

Media Contact:

Traders News Source
Mark Roberts, Senior Editor/Interviewer
This email address is being protected from spambots. You need JavaScript enabled to view it.